UK-based NextGen Group announced this week it has completed the formation of a diagnostics subsidiary to develop tests for central nervous system disorders.The new firm called NextGen Sciences Dx and headquartered in Boston, will focus on the discovery of biomarkers for the development of tests for disorders, such as Parkinson's disease, dementia, and traumatic brain injury. The tests will provide information on whether patients may have the disease and allow physicians to monitor changes in their conditions. Additionally, NextGen said, clinicians and pharmaceutical firms would be able to use the tests to determine the efficacy of therapeutic treatments.
